Page last updated: 2024-09-05

dabigatran and Complications of Diabetes Mellitus

dabigatran has been researched along with Complications of Diabetes Mellitus in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Aimo, A; De Caterina, R; Petricciuolo, S	1
Cheng, HM; Hsu, CC; Hsu, PF; Huang, CJ; Sung, SH; Tu, ST; Yu, BH	1
Diener, HC	1

Reviews

1 review(s) available for dabigatran and Complications of Diabetes Mellitus

Article	Year
[Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease]. Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:1 Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Complications; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Off-Label Use; Prevalence; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Sex Factors; Sleep Apnea, Obstructive; Stroke; Thiazoles; Thromboembolism	2020

Article

Year

[Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease].

Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:1

Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Complications; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Off-Label Use; Prevalence; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Sex Factors; Sleep Apnea, Obstructive; Stroke; Thiazoles; Thromboembolism

2020

Other Studies

2 other study(ies) available for dabigatran and Complications of Diabetes Mellitus

Article	Year
Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban. Thrombosis and haemostasis, 2018, Volume: 118, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Patient Safety; Proportional Hazards Models; Risk; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Treatment Outcome; Warfarin	2018
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.". Thrombosis and haemostasis, 2013, Volume: 110, Issue:3 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2013

Article

Year

Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban.

Thrombosis and haemostasis, 2018, Volume: 118, Issue:1

Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Patient Safety; Proportional Hazards Models; Risk; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Treatment Outcome; Warfarin

2018

Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".

Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin

2013